A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Brexpiprazole (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 08 Oct 2018 Planned number of patients changed from 387 to 480.
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.